This article is more than 6 months old
05/04/2021
|
Alba Tobella

The second vaccine developed in Russia is EpiVacCorona. There is still little information about this vaccine, which has already been approved by the government, but as of 19 March was not yet being used to immunise the population. 

Manufactured by the State Research Center of Virology and Biotechnology VECTOR, EpiVacCorona is a vaccine based on synthetic peptides. Its composition includes a synthetic version of SARS-CoV-2 protein fragments (or peptides) to trigger the immune response in the body. The phase III clinical trial began in November 2020 and involved about 3,000 volunteers from Russia. The results have not yet been published, but officials assured that it offered 100% efficacy during phases I and II. It consists of two doses, administered over 21 to 28 days. 

It is not known at this stage whether it causes adverse reactions and there is no information on the temperature at which it should be stored.

Vaccines
Whatsapp icono

Envia'ns per WhatsApp el que vulguis verificar i ens hi posarem
695 225 233

Educació en l'era de la desinformació
Projectes d'alfabetització mediàtica i informacional per promoure una ciutadania crítica
Desfake
Icone
Et necessitem

Amb la teva aportació contribuiràs a un debat polític més saludable i ajudaràs a impulsar projectes educatius per ensenyar a navegar el caos informatiu i a defensar-se de la desinformació.

Articles relacionats

  • Bacteria do not wait five seconds to jump onto your food after it falls on the floor

  • There is no proof that cracking your knuckles harms your joints

  • At-home genetics tests are accurate for determining ancestral origins, but not for predicting diseases

Especials

Nothing Found